Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma. - Burton EM; Milton DR; Tetzlaff MT; Wani K; Ross MI; Postow MA; Lazcano R; Glitza IC; Wong MK; Patel SP; Diab A; Gershenwald JE; et al. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025)